94 related articles for article (PubMed ID: 9459615)
1. Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities.
Chebath J; Fischer D; Kumar A; Oh JW; Kolett O; Lapidot T; Fischer M; Rose-John S; Nagler A; Slavin S; Revel M
Eur Cytokine Netw; 1997 Dec; 8(4):359-65. PubMed ID: 9459615
[TBL] [Abstract][Full Text] [Related]
2. Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors.
Kimura T; Wang J; Minamiguchi H; Fujiki H; Harada S; Okuda K; Kaneko H; Yokota S; Yasukawa K; Abe T; Sonoda Y
Stem Cells; 2000; 18(6):444-52. PubMed ID: 11072033
[TBL] [Abstract][Full Text] [Related]
3. [Effect of IL-6/sIL-6R on ex vivo expansion of human cord blood derived CD34+ cells].
Feng JF; Zhuang M; Zhu LJ; Sheng ZL; Zhu YQ; Li CP
Ai Zheng; 2004 Jun; 23(6):715-8. PubMed ID: 15191679
[TBL] [Abstract][Full Text] [Related]
4. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion.
Fischer M; Goldschmitt J; Peschel C; Brakenhoff JP; Kallen KJ; Wollmer A; Grötzinger J; Rose-John S
Nat Biotechnol; 1997 Feb; 15(2):142-5. PubMed ID: 9035138
[TBL] [Abstract][Full Text] [Related]
5. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor.
Ueda T; Tsuji K; Yoshino H; Ebihara Y; Yagasaki H; Hisakawa H; Mitsui T; Manabe A; Tanaka R; Kobayashi K; Ito M; Yasukawa K; Nakahata T
J Clin Invest; 2000 Apr; 105(7):1013-21. PubMed ID: 10749580
[TBL] [Abstract][Full Text] [Related]
6. [Cord blood transplantation and ex vivo expansion of hematopoietic stem cells].
Nakahata T
Rinsho Byori; 1999 May; Suppl 110():54-62. PubMed ID: 10475032
[TBL] [Abstract][Full Text] [Related]
7. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells.
Oh JW; Katz A; Harroch S; Eisenbach L; Revel M; Chebath J
Oncogene; 1997 Jul; 15(5):569-77. PubMed ID: 9247310
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
9. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.
Ozbek S; Peters M; Breuhahn K; Mann A; Blessing M; Fischer M; Schirmacher P; Mackiewicz A; Rose-John S
Oncogene; 2001 Feb; 20(8):972-9. PubMed ID: 11314032
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin 6 receptor is biologically active in vivo.
Mackiewicz A; Wiznerowicz M; Roeb E; Karczewska A; Nowak J; Heinrich PC; Rose-John S
Cytokine; 1995 Feb; 7(2):142-9. PubMed ID: 7780033
[TBL] [Abstract][Full Text] [Related]
11. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
[TBL] [Abstract][Full Text] [Related]
12. Flt 3 ligand, MGDF, Epo and G-CSF enhance ex vivo expansion of hematopoietic cell compartments in the presence of SCF, IL-3 and IL-6.
Kobari L; Giarratana MC; Poloni A; Firat H; Labopin M; Gorin NC; Douay L
Bone Marrow Transplant; 1998 Apr; 21(8):759-67. PubMed ID: 9603398
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+).
Weimar IS; Miranda N; Muller EJ; Hekman A; Kerst JM; de Gast GC; Gerritsen WR
Exp Hematol; 1998 Aug; 26(9):885-94. PubMed ID: 9694510
[TBL] [Abstract][Full Text] [Related]
14. Influence of FL on ex vivo expansion of hematopoietic cells from cord blood in long-term liquid cultures.
Zhang X; Cai H; Zhao J; Tan W; Yu J
Chin J Biotechnol; 1999; 15(3):189-94. PubMed ID: 10935167
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+ megakaryocytic cells.
Lazzari L; Henschler R; Lecchi L; Rebulla P; Mertelsmann R; Sirchia G
Haematologica; 2000 Jan; 85(1):25-30. PubMed ID: 10629587
[TBL] [Abstract][Full Text] [Related]
16. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
17. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of hematopoietic progenitor cells towards the myeloid and B-lymphoid lineage by hepatocyte growth factor (HGF) and thrombopoietin (TPO) together with early acting cytokines.
Grassinger J; Mueller G; Zaiss M; Kunz-Schughart LA; Andreesen R; Hennemann B
Eur J Haematol; 2006 Aug; 77(2):134-44. PubMed ID: 16856909
[TBL] [Abstract][Full Text] [Related]
19. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression.
Oh JW; Van Wagoner NJ; Rose-John S; Benveniste EN
J Immunol; 1998 Nov; 161(9):4992-9. PubMed ID: 9794436
[TBL] [Abstract][Full Text] [Related]
20. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis.
Wagley Y; Yoo YC; Seo HG; Rhee MH; Kim TH; Kang KW; Nah SY; Oh JW
Biochem Biophys Res Commun; 2007 Mar; 354(4):985-91. PubMed ID: 17274948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
